Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Linhaliq
- Development stage
- Discontinued
- Lead developer
- Paradigm Biopharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
Linhaliq (formerly known as Pulmaquin or ARD-3150) is an inhaled antibiotic formulation developed by Aradigm Corporation for the treatment of chronic *Pseudomonas aeruginosa* lung infections, particularly in patients with non-cystic fibrosis bronchiectasis (NCFB) and cystic fibrosis. The drug was developed in two primary forms: a purely liposomal ciprofloxacin formulation (Lipoquin, ARD-3100, or CFI) and a dual-release formulation (Pulmaquin, ARD-3150, or DRCFI) which consists of a mixture of liposome-encapsulated and unencapsulated (free) ciprofloxacin. This dual-release mechanism is designed to provide an immediate peak of the antibiotic in the lungs followed by sustained release over 24 hours, allowing for once-daily dosing while maintaining high local concentrations and minimizing systemic exposure. Linhaliq was evaluated in the Phase 3 ORBIT-3 and ORBIT-4 clinical trials. Despite showing efficacy in reducing pulmonary exacerbations in some populations, the FDA issued a Complete Response Letter in 2018, and the program was subsequently discontinued following Aradigm's liquidation in 2020.
- Brand names
- Linhaliq
- Other names
- Liposomal ciprofloxacinCiprofloxacin for inhalationDual-release ciprofloxacin for inhalation
02
Targets
NeuraminidaseDNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on Linhaliq.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Linhaliq.